Skip to main navigation
Skip to search
Skip to main content
Arizona Board of Regents Home
Search content at Arizona Board of Regents
Home
Profiles
Departments and Centers
Scholarly Works
Grants
Activities
Equipment
Datasets
Press/Media
Prizes
The role of the CTLA4 blockade in the treatment of malignant melanoma
Lee D. Cranmer
, Evan Hersh
Cancer Center Division
Research output
:
Contribution to journal
›
Review article
›
peer-review
54
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The role of the CTLA4 blockade in the treatment of malignant melanoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Immune Response
100%
Neoplasm
100%
CTLA-4
100%
Pharmacodynamics
100%
Metastatic Melanoma
100%
Mycobacterium Bovis BCG
100%
Ticilimumab
100%
Melanoma
100%
Diseases
100%
Cytokine
50%
Autoantibodies
50%
Specific Tumor
50%
Autoimmunity
50%
Homeostasis
50%
T Lymphocyte
50%
Ipilimumab
50%
Arthritis
50%
Immunosuppressive Drug
50%
T Lymphocyte Receptor
50%
Antigen Presenting Cell
50%
Supportive Care
50%
Steroid Therapy
50%
Topical Corticosteroid
50%
Colectomy
50%
Immune System
50%
Immunostimulating Agent
50%
Lymphocyte Antigen
50%
Human Monoclonal Antibody
50%
Dermatitis
50%
Uveitis
50%
Inflammatory Bowel Disease
50%
Effective Treatment
50%
Keyphrases
Clinical Benefit
100%
Malignant Melanoma
100%
Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4)
100%
Immune Breakthrough
100%
Metastatic Melanoma
50%
Melanoma
25%
Antibody-mediated
25%
Antigen-presenting Cells
25%
Immune System
25%
Immune Response
25%
Mechanism of Action
25%
Response Predictors
25%
Clinical Toxicity
25%
Autoantibodies
25%
Effective Treatment
25%
Monoclonal Antibody
25%
Tumor-specific
25%
Clinical Development
25%
Clinical Activity
25%
T Cell Receptor
25%
Inflammatory Bowel Disease
25%
Ipilimumab
25%
Toxicity Profile
25%
Safety Protocol
25%
Arthritis
25%
Safety Profile
25%
Anti-tumor Response
25%
Autoimmune
25%
Antitumor Immune Response
25%
Immunostimulant
25%
Antibody Titer
25%
Pharmacodynamics
25%
Supportive Care
25%
Homeostatic Mechanisms
25%
Mechanism Development
25%
Severe Cases
25%
Human Leukocyte Antigen
25%
Suppression Effect
25%
Bacille Calmette-Guérin
25%
Activated T Lymphocytes
25%
Colectomy
25%
Uveitis
25%
Immunosuppressive Cytokines
25%
Topical Steroid Therapy
25%
Toxicity Management
25%
Dermatitis
25%
Intravenous Steroids
25%
Tremelimumab
25%
Immunology and Microbiology
Immune Response
100%
CTLA-4
100%
Pharmacodynamics
100%
Mycobacterium Bovis BCG
100%
Tremelimumab
100%
Cytokine
50%
T Cell
50%
Autoimmunity
50%
Autoantibodies
50%
Homeostasis
50%
T Cell Receptor
50%
Ipilimumab
50%
Antibody Titer
50%
Immunostimulant
50%
Immunosuppressive Drug
50%
Inflammatory Bowel Disease
50%
Arthritis
50%
Human Monoclonal Antibody
50%
Antigen-Presenting Cell
50%
Uveitis
50%
Dermatitis
50%
Lymphocyte Antigen
50%
Immune System
50%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Neoplasm
100%
Cytotoxic T Lymphocyte Antigen 4
100%
Metastatic Melanoma
66%
Mycobacterium Bovis BCG
66%
Tremelimumab
66%
Diseases
66%
Autoantibodies
33%
Ipilimumab
33%
Cytokine
33%
Immunosuppressive Agent
33%
Antigen
33%
Pharmacodynamics
33%
T Lymphocyte Receptor
33%
Topical Corticosteroid
33%
Inflammatory Bowel Disease
33%
Arthritis
33%
Dermatitis
33%
Immunostimulant
33%
Human Monoclonal Antibody
33%
Lymphocyte Antigen
33%
Uveitis
33%
Pharmacodynamic Parameter
33%